- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) to launch its adrenaline autoinjector (AAI), Jext®, in
China via a partnership with leading supplier of adrenaline, Grandpharma. - Jext® is expected to be the first AAI to market in
China . Prior to registration in mainlandChina , Grandpharma plans to start selling Jext® in southernChina under a special licence linked to the existing registration of Jext® inHong Kong . - ALK will receive upfront and registration milestone payments totalling
EUR 12 million (~DKK 90 million ) in return for granting Grandpharma the exclusive rights to Jext® inChina . ALK will also manufacture and supply Jext® and receive revenue from the sale of products to Grandpharma. - Agreement is expected to accelerate ALK's long-term growth and supports its earnings aspirations.
ALK and the pharmaceutical company China Grand Pharmaceutical and Healthcare Holdings Limited (”Grandpharma”) today announced an exclusive licensing agreement that will see ALK’s AAI Jext® registered and launched in
Grandpharma is the leading supplier of adrenaline ampoules in
AAIs are used for the emergency treatment of acute allergic reactions – also known as anaphylaxis – which can be triggered by exposure to certain foods such as egg, cow’s milk, shellfish and nuts or by exposure to venom from bee and wasp stings. Currently, there are no AAIs registered in
Dr.
ALK’s existing business in
Under the terms of the new agreement ALK will receive upfront and registration milestone payments totalling
The agreement with Grandpharma is expected to accelerate ALK's long-term growth and support its earnings aspirations. According to the agreement ALK will receive an upfront payment, milestone payment according to the progress of registration activities for greater
ALK-Abelló A/S
For further information please contact:
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Media: Jeppe Ilkjær, mobile +45 3050 2014
This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.
About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm,
About Grandpharma
China Grand Pharmaceutical and Healthcare Holdings Limited (512.HK) is an international pharmaceutical company of technological innovation. The core products of the Group cover several major businesses represented by the anti-tumour, cardiovascular emergency pharmaceutical products and advanced cerebro-cardiovascular intervention advanced medical devices, anti-virus and anti-infection, respiratory and ENT, bio-health products and specialised pharmaceutical ingredients. The Group has mainly focused on four business scopes, namely “innovative drugs with high entry barriers”, “branded drugs”, “integration of raw materials”, and “nutrition products”. There are three major segments of global innovation and technology leadership, namely precision interventional therapy, Radionuclide–drug conjugate (“RDC”) and immunotherapy, to be carried out with a forward-looking view by the Group. Find more information at http://chinagrandpharm.com.
Attachment
- FM_13_21UK_30072021
Source:
2021 GlobeNewswire, Inc., source